SEIU Healthcare Training Centre Receives $500,000 in Funding from Government of Canada to Support Internationally Educated Nurses
RICHMOND HILL, ON, June 17, 2025 /CNW/ - The Government of Canada, through the Future Skills Centre (FSC), has awarded over $500,000 in funding to accelerate the growth of the SEIU Healthcare Training Centre's Internationally Educated Nurse (IEN) Career Pathway Program.
50 IENs will be trained through this investment, which reflects the union's training centre impact on solving healthcare staffing needs by supporting internationally trained nurses. The first cohort of trained nurses will have jobs secured at different employer partners, including Sienna Senior Living nursing homes.
The IEN Career Pathway Program is designed to break down the systemic barriers that internationally educated nurses often face when entering the Canadian healthcare system. By offering personalized case management, financial support, and targeted training, the SEIU Healthcare Training Centre program better equips participants with the tools they need to transition smoothly into the Canadian workforce.
QUOTES:
"Today's investment to support internationally educated nurses in becoming fully licensed and working to their full potential is proof of what's possible when unions and governments collaborate to create meaningful solutions. With our IEN Career Pathway Program, SEIU is not only helping IENs thrive, we're strengthening Canada's healthcare system with a more inclusive and skilled workforce." – Tyler Downey, President of SEIU Healthcare
"Nurses and healthcare professionals play a crucial role in keeping Canadians healthy. By facilitating the training of more nurses, we are enhancing the strength of our healthcare system. The SEIU Healthcare Training Centre is supporting internationally educated nurses through this program, ultimately ensuring that more patients receive the care they deserve." – The Honourable Marjorie Michel, Canada's Minister of Health
The SEIU Healthcare Training Centre is Canada's first union-led training institution, committed to empowering healthcare workers with the education, support, and career pathways they need to thrive.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Ottawa Citizen
an hour ago
- Ottawa Citizen
Dakroury: Fireworks are perilous to people, animals and the planet
I'm all for celebration: national pride, community spirit and giving children those magical memories of sparkly skies and loud booms. I get it, it's fun. But while the show may last only a few dazzling minutes, the impact lingers far longer. Fireworks in our capital city aren't as harmless as they seem. I know it's an unpopular opinion, but it's worth opening that Pandora's box. Article content Article content I'm also a worried citizen, a pet owner and eco-individual living in our city, trying to make sense of it all. While we're launching joy into the sky, we're also launching smoke, debris and sometimes chaos into the lives of animals, lungs and our already-struggling green spaces — especially during wildfire season, when one rogue spark could mean disaster. Article content Article content Instead of focusing on what's obvious (fireworks are fun, sure), let's talk about what comes after: the health effects on people, the distress caused to animals, the strain on our environment and the risks to public safety. It is time we sincerely explored safer, greener alternatives for national celebrations — along with more sensible bylaws to regulate how and where fireworks are sold. Article content To establish the extent of the issue, the Government of Canada's Health Infobase reported 210 fireworks-related injuries between April 2011 and April 2023. Most incidents occurred between May and August, especially around Victoria Day and Canada Day. Burns were the most common injury, followed by eye injuries. Nearly three-quarters of injured individuals required emergency treatment, and more than 11 per cent were hospitalized. Article content Article content Let's tackle the first major issue: pollution. A 2024 study in Québec claimed fireworks cause only minimal and localized air pollution. However, health experts argue that even low levels of air pollution can be harmful. Ève Riopel of L'association québécoise des médecins pour l'environnement emphasized that 'there is no safe level of air pollution.' Epidemiologist Paul Villeneuve added that short-term spikes in fine particulate matter (PM2.5) — which fireworks produce — are linked to increased hospital visits for asthma and other respiratory issues. The World Health Organization's Global Air Quality Guidelines identify pollutants like PM2.5, PM10, NO₂, and SO₂ as harmful even at low levels. Article content Article content Studies show fireworks can 'increase air pollutants by 42%, damage the ozone layer, and spike PM2.5 levels up to tenfold.'
Cision Canada
an hour ago
- Cision Canada
Innocan Pharma Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference
, June 20, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces that the recently published narrative review titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review" (DOI: has been officially accepted for presentation at PAINWEEK 2025, the national conference on pain management, taking place this September in Las Vegas, Nevada. PAINWEEK is a prestigious event that brings together leading clinicians, researchers, and educators in the field of pain medicine, offering a unique platform to showcase innovative research and best practices. The narrative review, selected through a competitive peer-review process, provides important insights into the potential of synthetic cannabidiol (CBD), administered through extended-release formulations, as a well-tolerated, non-opioid analgesic alternative. Innocan is developing LPT-CBD, an innovative injectable liposomal drug product designed for the sustained release of synthetic CBD. Supported by multiple animal studies, LPT-CBD has demonstrated steady plasma CBD levels for up to four weeks, prolonged pain relief, and excellent tolerability—offering a promising alternative to current opioid medications and addressing the urgent need to reduce opioid dependency. LPT-CBD will be showcased at the PAINWEEK conference to thousands of healthcare professionals and potential pharmaceutical partners, positioning it at the forefront of groundbreaking non-opioid chronic pain management solutions. "We are honored to be included among the esteemed voices presenting at PAINWEEK this year," said Iris Bincovich, Chief Executive Officer of Innocan."This recognition underscores our commitment to advancing evidence-based pain care and contributing meaningful research to the field." About Innocan: Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales. Contact Information: For Innocan Pharma Corporation: Iris Bincovich, CEO +1 5162104025 +972-54-3012842 +442037699377 [email protected] NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. Caution Regarding Forward-Looking Information Certain information set forth in this news release, including, without limitation, the Company's plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements. Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Cision Canada
7 hours ago
- Cision Canada
Over $7.7M in Ontario-Based Platforms to Advance Open Science and Brain Health Innovation Français
Two cutting-edge platforms at CAMH and Western University aim to accelerate AI-driven brain research and global data sharing TORONTO, June 20, 2025 /CNW/ - Brain Canada is pleased to announce an investment of more than $7.7 million to support two innovative research platforms based in Ontario that will drive forward brain health discovery, data sharing, and open science collaboration. Funded through the Canada Brain Research Fund (CBRF), a visionary partnership between Brain Canada and the Government of Canada, through Health Canada, these two projects will provide Canadian and international researchers with the tools and infrastructure they need to transform how brain disorders are studied, understood, and treated. "Through the Canada Brain Research Fund, the Government of Canada is pleased to support these two essential and innovative research initiatives, which will help drive new discoveries and improve care for people affected by neurological conditions," said the Honourable Marjorie Michel, Minister of Health. The newly supported platforms are the Brain Health Data Challenge (BHDC) platform, led by Dr. Tristan Glatard at the Centre for Addiction and Mental Health (CAMH), and the Mesoscopic Integrated Neuroimaging Data (MIND) Platform, led by Dr. Ali Khan at Western University. "Canada is at the forefront of a global shift toward open science in brain research," said Dr. Viviane Poupon, President and CEO of Brain Canada. "These two platforms exemplify how we can responsibly share data, scale innovation, and build collaborative networks to unlock the full potential of neuroscience and AI." ABOUT THE PROJECTS Building Reproducible AI Frameworks for Brain Health with the Brain Health Data Challenge Platform Tristan Glatard, Centre for Addiction and Mental Health (CAMH) (Grant total: $4.9M) With vast amounts of brain health data now available, artificial intelligence is revolutionizing how we understand, diagnose, and treat neurological conditions. However, data privacy regulations often prevent this information from being used in open AI challenges—a key method that has already accelerated innovation in fields like cancer and medical imaging. The BHDC platform will create a secure, privacy-compliant framework to enable AI competitions using Canadian brain health data. By unlocking these datasets for responsible and collaborative use, the platform will foster the development of reproducible and equitable AI models, helping clinicians tailor treatments and improve care for people living with brain disorders. "With this transformative investment from Brain Canada, CAMH is proud to lead the development of a secure and robust framework for ethical AI in mental health," said Dr. Aristotle Voineskos, SVP of Research and Science, CAMH. "The Brain Health Data Challenge will empower researchers globally to address complex brain health questions using advanced data science—while upholding the highest standards of privacy and equity. By enabling predictive, reproducible AI for serious mental illness, we move closer to better care, earlier interventions and improved quality of life." The Mesoscopic Integrated Neuroimaging Data (MIND) Platform Ali Khan, Western University (Grant total: $2.9 million) The MIND Platform combines ultra-powerful MRI and lightsheet microscopy, which enables researchers to see the brain's structure and activity in unprecedented detail. By linking images of living brains with detailed microscopy of brain tissue, scientists can gain deeper insights into how diseases like Alzheimer's or Parkinson's progress, affect brain circuits, and can be treated. The MIND Platform builds on two internationally recognized imaging facilities at Western University to create a centralized, standardized repository for high-resolution brain tissue data. Through a user-friendly online portal, researchers around the world will be able to send brain tissue for imaging and access powerful tools to analyze the data—without requiring advanced infrastructure at every site. By adopting global data standards and a robust open science framework, the MIND Platform will fuel national and international collaboration, enabling deeper understanding of brain structure, function, and disease. "Western is internationally recognized for its strengths in neuroimaging, with a long history of innovation and collaboration," said Robert Bartha, Vice Dean of Research and Innovation at Western's Schulich School of Medicine & Dentistry. "The MIND Platform builds on that foundation, pairing powerful imaging technologies with open science to push the boundaries of how we explore and understand the brain." Together, these platforms mark a major step forward in Canada's leadership in brain research, making it easier for scientists to share knowledge, build on each other's work, and transform brain health through open, data-driven innovation. About Brain Canada Brain Canada is a national charitable organization that enables and supports excellent, innovative, and collaborative brain research in Canada. Through the Canada Brain Research Fund, a public-private partnership with the Government of Canada through Health Canada, Brain Canada funds initiatives that advance knowledge, drive innovation, and accelerate the development of diagnostics, treatments, and cures. About the Centre for Addiction and Mental Health (CAMH) The Centre for Addiction and Mental Health (CAMH) is Canada's largest mental health and addiction teaching hospital and a world leading research centre in this field. CAMH combines clinical care, research, education, policy development and health promotion to help transform the lives of people affected by mental illness and addiction. CAMH is fully affiliated with the University of Toronto and is a Pan American Health Organization/World Health Organization Collaborating Centre. For more information, please visit or follow @CAMHnews on Bluesky and LinkedIn. About Western University Western University delivers an academic experience second to none. Since 1878, The Western Experience has combined academic excellence with life-long opportunities for intellectual, social and cultural growth in order to better serve our communities. Our research excellence expands knowledge and drives discovery with real-world application. Western attracts individuals with a broad worldview, seeking to study, influence and lead in the international community. CAMH [email protected] Western University Crystal Mackay Director, Media Relations m. 519-933-5944 e. [email protected] Brain Canada Kate Shingler, Senior Director, Strategic Communications [email protected] 514-550-8308 SOURCE Brain Canada
